Overview

Endostar Combined With NVB and DDP Second-line Treatment of Advanced Esophageal Squamous Cell Carcinomas

Status:
Unknown status
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to explore whether endostar combined with NVB and DDP as treatment could improve progression-free surial time (PFS) and to evaluate the safety of the chemotherapy regimens
Phase:
Phase 2
Details
Lead Sponsor:
Fudan University
Treatments:
Cisplatin
Endostar protein
Vinorelbine